• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HIV-1 感染企图自杀患者中依维韦仑/考比司他/恩曲他滨/替诺福韦艾拉酚胺药物过量。

Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.

机构信息

Infectious Diseases Unit, Internal Medicine Department, University Hospital of Ferrol, Avda. da Residencia, s/n, 15405, Ferrol, A Coruña, Spain.

Hospital Pharmacy, University Hospital of Ferrol, A Coruña, Spain.

出版信息

Infection. 2019 Feb;47(1):115-119. doi: 10.1007/s15010-018-1201-x. Epub 2018 Aug 25.

DOI:10.1007/s15010-018-1201-x
PMID:30145772
Abstract

INTRODUCTION

Data are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF).

MATERIAL AND METHODS

We present the first report of suicidal attempt with E/C/F/TAF in a Human Immunodeficiency Virus-infected subject.

RESULTS

A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed. E/C/F/TAF withdrawal resulted in favourable renal and neuropsychiatric outcomes. The suicide attempt seemed unrelated to the integrase strand transfer inhibitor, being evenly explained within the context of stressful personal conflicts.

CONCLUSION

A suicidal attempt with an E/C/F/TAF overdose in an HIV-infected patient, resulted in a favourable outcome from a renal and neuropsychiatric standpoint.

摘要

简介

关于艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺（E/C/F/TAF）用药过量的数据尚缺乏。

材料和方法

我们报告了首例人类免疫缺陷病毒感染患者服用 E/C/F/TAF 后试图自杀的病例。

结果

讨论了伴有可逆性急性肾功能衰竭而无近端肾小管病变和神经精神问题。停止使用 E/C/F/TAF 后，肾功能和神经精神状况均有改善。自杀企图似乎与整合酶链转移抑制剂无关，在压力性个人冲突的背景下可以得到合理的解释。

结论

在 HIV 感染患者中，E/C/F/TAF 用药过量导致试图自杀，从肾脏和神经精神方面来看，结果良好。

相似文献

1
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.HIV-1 感染企图自杀患者中依维韦仑/考比司他/恩曲他滨/替诺福韦艾拉酚胺药物过量。
Infection. 2019 Feb;47(1):115-119. doi: 10.1007/s15010-018-1201-x. Epub 2018 Aug 25.
2
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中，含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学：一项单臂、开放标签试验。
Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.
3
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.简短报告：转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片治疗方案在HIV-1/乙型肝炎合并感染成人中的疗效和安全性
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):294-298. doi: 10.1097/QAI.0000000000001069.
4
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.初治HIV-1患者接受埃替拉韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺治疗48周后罕见出现耐药性。
HIV Clin Trials. 2016 Mar;17(2):78-87. doi: 10.1080/15284336.2016.1142731.
5
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.简报：在病毒学抑制的女性中转换使用艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺（E/C/F/TAF）复方制剂的疗效和安全性。
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):209-213. doi: 10.1097/QAI.0000000000001663.
6
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯、艾维雷韦、考比司他、恩曲他滨复方制剂，用于治疗人类免疫缺陷病毒 1 型感染的初始治疗：两项随机、双盲、III 期、非劣效性试验。
Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.
7
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study.达芦那韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺用于初治HIV-1患者：3期AMBER研究的亚组分析
HIV Res Clin Pract. 2019 Feb;20(1):24-33. doi: 10.1080/15284336.2019.1608714. Epub 2019 May 29.
8
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.一项多中心、开放标签、3b 期、随机试验：在 HIV-1 病毒学抑制的 60 岁及以上人群中，将包含富马酸替诺福韦二吡呋酯的方案转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片复方制剂方案时，对骨矿物质密度的影响。
Lancet HIV. 2019 Oct;6(10):e655-e666. doi: 10.1016/S2352-3018(19)30195-X.
9
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺：用于治疗人类免疫缺陷病毒 1 型感染的综述。
Drugs. 2016 Jun;76(9):957-68. doi: 10.1007/s40265-016-0586-z.
10
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.简要报告：替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯随机双盲比较，二者均与埃替格韦、考比司他和恩曲他滨联合用于初治HIV-1感染：第96周结果
J Acquir Immune Defic Syndr. 2016 May 1;72(1):58-64. doi: 10.1097/QAI.0000000000000940.

引用本文的文献

1
Tenofovir alafenamide nephrotoxicity: a case report and literature review.替诺福韦艾拉酚胺肾毒性：一例病例报告及文献复习。
AIDS Res Ther. 2021 Aug 21;18(1):53. doi: 10.1186/s12981-021-00380-w.

本文引用的文献

1
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.从非核苷类逆转录酶抑制剂加复方恩曲他滨和替诺福韦酯方案转换为elvitegravir、考比司他、恩曲他滨和替诺福韦酯的单片复方制剂方案：STRATEGY-NNRTI研究96周结果
HIV Clin Trials. 2017 Jul;18(4):141-148. doi: 10.1080/15284336.2017.1338844. Epub 2017 Jul 9.
2
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI.将多片利托那韦增强型蛋白酶抑制剂联合恩曲他滨和替诺福韦酯复方制剂简化为埃替格韦、考比司他、恩曲他滨、替诺福韦酯单片复方制剂：STRATEGY-PI研究96周结果
HIV Clin Trials. 2017 May;18(3):118-125. doi: 10.1080/15284336.2017.1330440. Epub 2017 May 30.
3
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.简要报告：替诺福韦艾拉酚胺（TAF）与富马酸替诺福韦二吡呋酯（TDF）分别与埃替拉韦、考比司他和恩曲他滨（E/C/F）联合用于初治HIV-1感染的随机、双盲比较：第144周结果
J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):211-218. doi: 10.1097/QAI.0000000000001350.
4
Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.女性和老年患者中导致多替拉韦停药的神经精神不良事件发生率更高。
HIV Med. 2017 Jan;18(1):56-63. doi: 10.1111/hiv.12468. Epub 2016 Nov 10.
5
Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice.在现实临床实践中对含多替拉韦的联合抗逆转录病毒治疗方案的不耐受情况。
AIDS. 2016 Nov 28;30(18):2831-2834. doi: 10.1097/QAD.0000000000001279.
6
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.在初治的 HIV 感染青少年中，含有艾维雷韦、考比司他、恩曲他滨和替诺福韦艾拉酚胺的单片复方制剂的安全性、疗效和药代动力学：一项单臂、开放标签试验。
Lancet HIV. 2016 Dec;3(12):e561-e568. doi: 10.1016/S2352-3018(16)30121-7. Epub 2016 Oct 17.
7
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.一项评估在接受过治疗的HIV-1感染成人中换用埃替拉韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺加达拉韦林的随机、开放标签试验。
J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):193-200. doi: 10.1097/QAI.0000000000001193.
8
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.简短报告：在肾功能受损的HIV感染成人中换用与埃替拉韦、考比司他和恩曲他滨联合配方的替诺福韦艾拉酚胺：一项单臂、多中心、开放标签3期研究的96周结果
J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):180-184. doi: 10.1097/QAI.0000000000001186.
9
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.简短报告：转换为艾维雷韦/考比司他/恩曲他滨/替诺福韦艾拉酚胺单片治疗方案在HIV-1/乙型肝炎合并感染成人中的疗效和安全性
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):294-298. doi: 10.1097/QAI.0000000000001069.
10
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.从富马酸替诺福韦二吡呋酯转换为替诺福韦艾拉酚胺在 HIV-1 感染的病毒学抑制成人中的抗逆转录病毒治疗方案：一项随机、活性对照、多中心、开放性标签、3 期、非劣效性研究。
Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2.